Terns Pharmaceuticals, Inc (TERN) insider trading
Every open-market stock purchase and sale by Terns Pharmaceuticals, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Insiders sold $7.1M over the last 12 months (7 sales). No open-market buys.
- Last insider buy: Andrew Gengos (CFO), $19.6K, 15 months ago.
Last 12 months: insiders bought $0 (0 buys) and sold $7.1M (7 sales). Last close $52.95 on May 3, 2026.
Recent TERN insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| May 5, 2026 | Amy L. Burroughs (CEO) | Sold (not open market) | $11.2M |
| May 5, 2026 | Amy L. Burroughs (CEO) | Sold (not open market) | $9.1M |
| May 5, 2026 | Amy L. Burroughs (CEO) | Sold (not open market) | $8M |
| May 5, 2026 | Amy L. Burroughs (CEO) | Sold (not open market) | $7.8M |
| May 5, 2026 | Andrew Gengos (CFO) | Sold (not open market) | $5.1M |
| May 5, 2026 | Amy L. Burroughs (CEO) | Sold (not open market) | $4.4M |
| May 5, 2026 | Emil Kuriakose (C-suite exec) | Sold (not open market) | $4.3M |
| May 5, 2026 | Emil Kuriakose (C-suite exec) | Sold (not open market) | $4.2M |
| May 5, 2026 | Andrew Gengos (CFO) | Sold (not open market) | $3.6M |
| May 5, 2026 | Emil Kuriakose (C-suite exec) | Sold (not open market) | $3.6M |
| May 5, 2026 | Andrew Gengos (CFO) | Sold (not open market) | $2.8M |
| May 5, 2026 | Emil Kuriakose (C-suite exec) | Sold (not open market) | $2.3M |
| May 5, 2026 | Andrew Gengos (CFO) | Sold (not open market) | $2.1M |
| May 5, 2026 | Emil Kuriakose (C-suite exec) | Sold (not open market) | $1.3M |
| May 5, 2026 | Emil Kuriakose (C-suite exec) | Sold (not open market) | $791K |
| May 5, 2026 | Emil Kuriakose (C-suite exec) | Sold (not open market) | $642K |
| May 5, 2026 | Amy L. Burroughs (CEO) | Sold (not open market) | $441K |
| May 5, 2026 | Radhika Tripuraneni (Insider) | Sold (not open market) | $386K |
| May 5, 2026 | Jill M. Quigley (Insider) | Sold (not open market) | $386K |
| May 5, 2026 | David A Fellows (Insider) | Sold (not open market) | $386K |
| May 5, 2026 | Jeffrey B Kindler (Insider) | Sold (not open market) | $386K |
| May 5, 2026 | Robert Azelby (Insider) | Sold (not open market) | $372K |
| May 5, 2026 | Heather D Turner (Insider) | Sold (not open market) | $365K |
| May 5, 2026 | David A Fellows (Insider) | Sold (not open market) | $263K |
| May 5, 2026 | Jeffrey B Kindler (Insider) | Sold (not open market) | $263K |
Who's trading TERN
- Heather D Turner, Insider: other filings, last May 5, 2026
- Radhika Tripuraneni, Insider: other filings, last May 5, 2026
- David A Fellows, Insider: other filings, last May 5, 2026
- Amy L. Burroughs, CEO: sold $6.5M (8 sales), last May 5, 2026
- Andrew Gengos, CFO: other filings, last May 5, 2026
- Emil Kuriakose, C-suite exec: sold $94.2K (3 sales), last May 5, 2026
- Robert Azelby, Insider: other filings, last May 5, 2026
- Jill M. Quigley, Insider: sold $441K (1 sale), last May 5, 2026
- Jeffrey B Kindler, Insider: other filings, last May 5, 2026
Get free alerts when an insider at Terns Pharmaceuticals, Inc files a new trade →